Treating patients with early-stage, resected, node-positive non–small-cell lung cancer with customized chemotherapy based on BRCA1 expression levels did not increase overall survival rates.

This video examines results of a study that looked at treatment tolerability in elderly patients with HPV-positive oropharyngeal squamous cell carcinoma.

Participating in a 12-week physical exercise and psychosocial intervention improved the functional capacity of patients with advanced-stage lung cancer, which may result in improvement in quality of life, according to the results of a study presented at the World Conference on Lung Cancer.

A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.

The FDA has approved the CAR T-cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B-cell lymphomas in adults who have failed or relapsed after two or more prior treatments.

The pharmaceutical company AstraZeneca retracted a paper and acknowledged that some preclinical data were falsified regarding its developmental agent acalabrutinib, which is under investigation for use in a number of malignancies.

Small-cell lung cancer patients with high tumor burden treated with immunotherapy had greater objective response rate, progression-free survival, and overall survival compared with patients with medium or low tumor burden.

Quality of life was not improved with the use of early palliative care for patients recently diagnosed with malignant pleural mesothelioma, according to data presented at the World Conference on Lung Cancer.